We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PHASE 2 KEYNOTE‐667: PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL) WITH SLOW EARLY RESPONSE TO FRONT‐LINE CHEMOTHERAPY.
- Authors
Vinti, L.; Daw, S.; Alvarez, C. Sabado; Fagioli, F.; Beishuizen, A.; Michel, G.; Moleti, M. L.; Cepelova, M.; Thorwarth, A.; Rigaud, C.; Lopez de Sabando, D. Plaza; Landman‐Parker, J.; Shen, J.; Pillai, P.; Marinello, P.; Mauz‐Koerholz, C.
- Abstract
After consolidation, pts with PET positivity (Deauville score, 4/5 at late response assessment [LRA]) received involved-site RT (28.8 Gy) to late PET-positive residua. B Introduction: b Patients (pts) with cHL with slow early response (SER) to initial chemotherapy (chemo) have a high risk of relapse. Current treatments such as chemo dose intensification and radiotherapy (RT) can increase the risk of secondary malignancies and cause long-term toxicity.
- Subjects
YOUNG adults; HODGKIN'S disease; PEMBROLIZUMAB; CANCER chemotherapy; STOCK ownership
- Publication
Hematological Oncology, 2023, Vol 41, p66
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_31